Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK) , exercised 15,000 options for common stock and immediately sold the resulting shares in an open-market transaction totaling approximately $928,950, according to the SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value ~$928,950 Post-transaction shares (direct) Post-transaction value (direct ownership) ~$3.0 million Transaction value based on SEC Form 4 weighted average purchase price ($61.93); post-transaction value based on Feb. 5, 2026 market close ($60.24). Key questions How significant is this transaction relative to Callos' historical selling activity? This disposition of 15,000 shares is materially larger than Callos' recent median sell transaction of 2,886 shares and represents a higher percentage of his remaining holdings compared to prior sales, reflecting limited remaining capacity after substanti
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
- Cytokinetics (CYTK) had its price target raised by Mizuho from $84.00 to $100.00. They now have an "outperform" rating on the stock.MarketBeat
- Cytokinetics (CYTK) had its price target raised by JPMorgan Chase & Co. from $74.00 to $75.00. They now have an "overweight" rating on the stock.MarketBeat
- Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo [Yahoo! Finance]Yahoo! Finance
CYTK
Earnings
- 2/24/26 - Miss
CYTK
Sec Filings
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- CYTK's page on the SEC website